This trial is testing rituximab, lenalidomide, acalabrutinib, tafasitamab to see if they can help control non-germinal center diffuse large B-cell lymphoma.
- Non-Hodgkin's Lymphoma
2 Primary · 3 Secondary · Reporting Duration: Time between study entry and death from any cause, assessed up to 2 years post-treatment
Side Effects for
Awards & Highlights
1 Treatment Group
Treatment (uLTRA, CHOP)
1 of 1
60 Total Participants · 1 Treatment Group
Primary Treatment: Rituximab · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What other clinical examinations have been conducted utilizing Rituximab?
"At present, 1750 clinical trials are being conducted to study the efficacy of Rituximab. Of these, 377 have entered Phase 3 and can be found across 69161 locations with a majority in Joliet, Illinois." - Anonymous Online Contributor
Has the FDA sanctioned Rituximab as a safe and effective drug?
"The safety of Rituximab has been estimated by the Power team to be a 2, as its efficacy is yet unproven but some supporting data exists for its safety." - Anonymous Online Contributor
What types of treatments is Rituximab commonly prescribed for?
"Rituximab can be employed to treat pheochromocytomas, ulcerative colitis, as well as varicella-zoster virus acute retinal necrosis." - Anonymous Online Contributor
Are there opportunities to become involved in this investigation?
"Affirmative. Clinicaltrials.gov data corroborates that this research is actively recruiting, with the first listing being posted on March 3rd 2022 and last update occurring on July 10th of the same year. The study requires 60 individuals from a single medical facility to participate in its activities." - Anonymous Online Contributor
What is the scope of subjects currently under evaluation in this clinical exploration?
"Affirmative. According to information in clinicaltrials.gov, this medical study initially opened for recruitment on March 3rd 2022 and has recently been updated on July 10th 2022. This research requires 60 participants based at a single site." - Anonymous Online Contributor